Pre-Clinical Cytokine Drug Development: An Analysis of the Latest Data

As the pharmaceutical industry invests significantly in the development of cytokine drugs, preclinical data has become a crucial field for insights and innovation. With almost a third of cytokine drugs currently in the active preclinical phase, we dive deep into the data that fuels this evolution.

This review showcases a shift towards immunocytokines and armored cell therapies, emphasizing the rise of IL-15. Uncover intriguing insights on which animals are driving this research, whilst exploring emerging drug targets and their potential clinical applications. From global trends to IND approvals and the balance between oncology and non-oncology applications, this report is your essential guide to the future of cytokine therapies.